Literature DB >> 28187730

Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation.

Scott A Chapman1, Catherine A St Hill1, Meg M Little2, Michael T Swanoski2, Shellina R Scheiner1, Kenric B Ware3, M Nawal Lutfiyya4,5.   

Abstract

BACKGROUND: Ischemic stroke is a risk associated with atrial fibrillation (AF) and is estimated to occur five times more often in afflicted patients than in those without AF. Anti-thrombotic therapy is recommended for the prevention of ischemic stroke. Risk stratification tools, such as the CHADS2, and more recently the CHA2DS2-VASc, for predicting stroke in patients with AF have been developed to determine the level of stroke risk and assist clinicians in the selection of antithrombotic therapy. Warfarin, for stroke prevention in AF, is the most commonly prescribed anticoagulant in North America. The purpose of this study was to examine the utility of using the CHADS2 score levels (low and high) in contrast to the CHA2DS2-VASc when examining the outcome of warfarin prescriptions for adult patients with AF. The CHA2DS2-VASc tool was not widely used in 2010, when the data analyzed were collected. It has only been since 2014 that CHA2DS2-VASc criteria has been recommended to guide anticoagulant treatment in updated AF treatment guidelines.
METHODS: Bivariate and multivariate data analysis strategies were used to analyze 2010 National Ambulatory Care Survey (NAMCS) data. NAMCS is designed to collect data on the use and provision of ambulatory care services nationwide. The study population for this research was US adults with a diagnosis of AF. Warfarin prescription was the dependent variable for this study. The study population was 7,669,844 AF patients.
RESULTS: Bivariate analysis revealed that of those AF patients with a high CHADS2 score, 25.1% had received a warfarin prescription and 18.8 for those with a high CHA2DS2-VASc score. Logistic regression analysis yielded that patients with AF had higher odds of having a warfarin prescription if they had a high CHADS2 score, were Caucasian, lived in a zip code where < 20% of the population had a university education, and lived in a zip code where < 10% of the population were living in households with incomes below the federal poverty level. Further, the analysis yielded that patients with AF had lesser odds of having a warfarin prescription if they were ≥ 65 years of age, female, or had health insurance.
CONCLUSIONS: Overall, warfarin appears to be under-prescribed for patients with AF regardless of the risk stratification system used. Based on the key findings of our study opportunities for interventions are present to improve guideline adherence in alignment with risk stratification for stroke prevention. Interprofessional health care teams can provide improved medical management of stroke prevention for patients with AF. These interprofessional health care teams should be constituted of primary care providers (physicians, physician assistants, and nurse practitioners), nurses (RN, LPN), and pharmacists (PharmD, RPh).

Entities:  

Keywords:  Anti-coagulation; Atrial fibrillation; CHA2DS2-VASc; CHADS2; Guideline Adherence; Interprofessional health care teams; Stroke; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28187730      PMCID: PMC5303258          DOI: 10.1186/s12913-017-2025-6

Source DB:  PubMed          Journal:  BMC Health Serv Res        ISSN: 1472-6963            Impact factor:   2.655


  37 in total

1.  The triple aim: care, health, and cost.

Authors:  Donald M Berwick; Thomas W Nolan; John Whittington
Journal:  Health Aff (Millwood)       Date:  2008 May-Jun       Impact factor: 6.301

2.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

3.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?

Authors:  Peter J Zimetbaum; Amit Thosani; Hsing-Ting Yu; Yan Xiong; Jay Lin; Prajesh Kothawala; Matthew Emons
Journal:  Am J Med       Date:  2010-05       Impact factor: 4.965

4.  Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Authors:  Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum
Journal:  Value Health       Date:  2006 Sep-Oct       Impact factor: 5.725

5.  Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007.

Authors:  Axel C Carlsson; Per Wändell; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist
Journal:  Eur J Clin Pharmacol       Date:  2012-06-10       Impact factor: 2.953

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.

Authors:  Julian P Casciano; Daniel E Singer; Winghan Jacqueline Kwong; Eben S Fox; Bradley C Martin
Journal:  Am J Cardiovasc Drugs       Date:  2012-10-01       Impact factor: 3.571

9.  Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation.

Authors:  William R Lewis; Gregg C Fonarow; Kenneth A LaBresh; Christopher P Cannon; Wenqin Pan; Dennis M Super; Suzanne A Sorof; Lee H Schwamm
Journal:  Am J Cardiol       Date:  2008-11-07       Impact factor: 2.778

10.  Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010.

Authors:  Gautam R Shroff; Craig A Solid; Charles A Herzog
Journal:  J Am Heart Assoc       Date:  2014-06-03       Impact factor: 5.501

View more
  4 in total

1.  Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.

Authors:  Azraa Amroze; Kathleen Mazor; Sybil Crawford; Kevin O'Day; David D McManus; Alok Kapoor
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Effects of Cognitive Behavior Therapy on Depression, Illness Perception, and Quality of Life in Atrial Fibrillation Patients.

Authors:  Qu Shan; Shi Xinxin; Xie Zhijuan; Ding Rongjing; Zheng Minjie
Journal:  Front Psychiatry       Date:  2022-05-06       Impact factor: 4.157

3.  Impact of social determinants of health on anticoagulant use among patients with atrial fibrillation: Systemic review and meta-analysis.

Authors:  Rasha Khatib; Nicole Glowacki; John Byrne; Peter Brady
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

4.  Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis.

Authors:  Hong Lei; Li-Ting Yu; Wei-Ning Wang; Shun-Guo Zhang
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.